KRAS G12V-specific TCR
/ Immupeutics Medicine
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
October 02, 2026
Functionally validated KRAS G12V-specific TCRs with high potency achieve in vivo T cell redirection via CD7-targeted LNPs
(SITC 2026)
- No abstract available
Preclinical • Oncology • CD7 • KRAS
1 to 1
Of
1
Go to page
1